Ads
related to: parp inhibitor ovarian cancer- Genomic Testing
Read How Testing Could
Help Inform Your Treatment Plan.
- Side Effect Information
Learn More About Potential Side
Effects And Safety Information.
- Oral Medication
Learn More About An Oral Treatment
Option For Ovarian Cancer.
- Clinical Study Data
Find Clinical Study Data
At The Patient Site.
- Genomic Testing
Search results
Results From The WOW.Com Content Network
Veliparib June 2014 in phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC). [29] Pamiparib (BGB-290) For ovarian cancer, 1st patient enrolled May 2018. [30] It is a PARP1 and PARP2 inhibitor. [31] [32] Started Phase II:
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults.It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
Fuzuloparib (trade name AiRuiYi) is a pharmaceutical drug for the treatment of ovarian cancer. [1] It is approved for use in China. [2] It is an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme. [3] It is also being studied for its potential use for the treatment of pancreatic, breast, prostate, and lung cancer. [2]
Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. [2] Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1).
Veliparib (ABT-888) [1] is a potential anti-cancer drug acting as a PARP inhibitor.It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments.
Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. [3] [4] [5] It is taken by mouth. [3] [4] It is a PARP inhibitor.
Ads
related to: parp inhibitor ovarian cancer